FibroGenesis, a developer of fibroblast-based therapeutic solutions for unmet medical needs, has entered into a manufacturing agreement with iBiologics to supply its proprietary allogeneic fibroblast cells to support FibroGenesis’s growing chronic disease platform and ongoing clinical trials.   “We are extremely pleased to partner with iBiologics to manufacture our breakthrough fibroblasts,” said Pete O’Heeron, chief executive officer, FibroGenesis. “Our collaborati...